|
CIPAMI
Clopidogrel to Improve Primary percutaneous coronary intervention in Acute Myocardial Infarction
Ongoing trial
 |
Author(s) |
Zeymer U, Arntz H-R, Darius H, Huber K, Senges J |
 |
Title(s) |
Efficacy and safety of clopidogrel 600 mg administered pre-hospitally to improve primary percutaneous coronary intervention in patients with acute myocardial infarction (CIPAMI): study rationale and design |
|
Reference(s) |
Cardiology 2007;108:265–72 |
|
Disease |
AMI |
|
Purpose |
To evaluate the efficacy and safety of clopidogrel in addition to standard ASA and heparin in the pre-hospital setting in patients with AMI scheduled for primary percutaneous coronary intervention |
|
Study design |
Randomised, open |
|
Follow-up |
7 days or hospital discharge |
|
Patients |
Aim 654 patients, aged ≥ 18 years, with acute ST elevation MI < 6 h |
|
Treatment regimen |
Clopidogrel, 600 mg loading dose, plus ASA, 500 mg iv, and heparin, 5000 U iv or enoxaparin, 0.5 mg/kg sc, followed by 1 mg/kg bid, or standard ASA and heparin/enoxaparin alone |
|
Results |
Not yet available |
|
|
|
